The most efficient protocols to date rely on the basal medium RPMI 1640 (which is chemically defined 13 ) supplemented with 'B27' , a complex mix of 21 components (many of animal origin), originally designed for the culture of hippocampal neurons 14 . It is unknown whether B27 components influence reproducibility of differentiation, maturation or subtype specification. Therefore, we sought to develop an optimized and low-cost cardiac differentiation protocol with no undefined or proprietary medium components, which would enable highly reproducible differentiation and allow further understanding of the macromolecules required for cardiac differentiation. Using our protocol, we reproducibly and efficiently differentiated 11 hiPSC lines (generated under chemically defined conditions) when tested repeatedly from passage 20 to passage 83, which represented >600 differentiations. We produced cardiomyocytes at >85% purity and enriched them to >95% using chemically defined metabolic selection.
results

A defined cardiac differentiation platform
We generated 11 pluripotent hiPSC lines under chemically defined conditions ( Supplementary Fig. 1 ) on a chemically synthesized vitronectin peptide substrate, with nonenzymatic passaging (Supplementary Fig. 2) . Early experiments had demonstrated that previous monolayer cardiac differentiation protocols 6 could be adapted to function with hiPSCs grown under chemically defined conditions (Supplementary Fig. 3 ). We concentrated on the three unrelated medium formulations that can support growth factor-based monolayer cardiac differentiation: RPMI medium with B27 supplement without insulin (RPMI + B27 − ins medium) 15 , supplemented StemPro-34 medium (ref. 16) , and low-insulin albumin polyvinylalcohol essential lipids (LI-APEL) medium 9 ( Supplementary Table 1 ). Initial experiments demonstrated that, of these three, RPMI + B27 − ins medium resulted in the most efficient cardiac differentiation. Starting with the 21 components of B27, we subtracted one component at a time and assessed cultures for continued high-efficiency differentiation ( Supplementary Table 2a -c). We also assessed components from StemPro-34 and LI-APEL media for potential benefits to differentiation ( Supplementary Table 2d -f). We concluded that hiPSC existing methods for human induced pluripotent stem cell (hiPsc) cardiac differentiation are efficient but require complex, undefined medium constituents that hinder further elucidation of the molecular mechanisms of cardiomyogenesis. using hiPscs derived under chemically defined conditions on synthetic matrices, we systematically developed an optimized cardiac differentiation strategy, using a chemically defined medium consisting of just three components: the basal medium rPmi 1640, l-ascorbic acid 2-phosphate and rice-derived recombinant human albumin. Along with small molecule-based induction of differentiation, this protocol produced contractile sheets of up to 95% tnnt2 + cardiomyocytes at a yield of up to 100 cardiomyocytes for every input pluripotent cell and was effective in 11 hiPsc lines tested. this chemically defined platform for cardiac specification of hiPscs will allow the elucidation of cardiomyocyte macromolecular and metabolic requirements and will provide a minimal system for the study of maturation and subtype specification.
hiPSCs are increasingly used in cardiovascular research, including in disease modeling, cardiotoxicity screening, drug discovery and the study of human cardiac development 1 . Furthermore, a major aim of the cardiac differentiation field is to provide cells for cellular therapy 1 . Each of these objectives requires large numbers (10 7 -10 9 ) of cells to be made in a scalable, cost-effective and reproducible fashion, ideally under chemically defined conditions free of animal-derived products.
Progress in differentiation techniques has yielded multiple methods that produce pure cardiac troponin T-positive (TNNT2 + ) cells with relative ease 2-6 . Methodological improvements have largely concentrated on mimicking the embryonic developmental signals that control mesoderm induction, activin-cardiac differentiation was successful in a medium consisting of just three components: RPMI 1640 basal medium, l-ascorbic acid 2-phosphate (AA 2-P) and bovine serum albumin (BSA) ( Supplementary Table 2g ).
optimization of a chemically defined medium
To render our formula chemically defined and free of animalderived products, we replaced BSA with recombinant human albumin (rHA; Supplementary Fig. 4a,b ). We found that AA 2-P was essential to the formula and observed complete cell death when we omitted it ( Supplementary Fig. 4c) . Although it was possible to differentiate cells without rHA in an entirely protein-free medium and obtain ~65% TNNT2 + cells, the total cell yield was drastically reduced, even when we varied doses of AA 2-P ( Supplementary  Fig. 4d ). Polyvinyl alcohol (PVA), which prevents shear stress in a similar manner to rHA, combined with varying doses of AA 2-P, also did not increase cardiomyocyte yield over that obtained in RPMI 1640 medium with AA 2-P alone. These data suggest that neither prevention of shear stress nor the antioxidant properties of rHA necessitate its inclusion in this formula. We termed our final medium formulation 'CDM3' for chemically defined medium, three components; we achieved efficient differentiation with this medium over a broader range (0.8 × 10 4 to 1.4 × 10 4 cells/cm 2 ) of initial seeding densities than those for RPMI + B27 − ins medium (1.2 × 10 4 to 1.4 × 10 4 cells/cm 2 ; Supplementary Figs. 3d and 4g) .
We also assessed six small molecules with GSK3B inhibitory activity to identify whether any of them increased mesoderm induction in CDM3. We observed that only the small molecules BIO and CHIR99021 induced cardiac differentiation; some others were highly toxic ( Supplementary Fig. 4h,i) . We also assessed small-molecule Wnt inhibitors, many of which were equally effective despite differences in the inhibition mechanism ( Supplementary Fig. 4j,k) . Next we analyzed the importance of the timing of canonical Wnt signaling activation with CHIR99021 and Wnt signaling inhibition with Wnt-C59: application of CHIR99021 for 2 d followed by Wnt-C59 for 2 d was optimal in CDM3 but not in RPMI + B27 − ins medium (Supplementary Table 3 ). The final protocol ( Fig. 1a ) resulted in production of cardiomyocytes at equivalent yields ( Fig. 1b ) and efficiencies to those obtained using our optimized protocol with RPMI + B27 − ins medium ( Fig. 1c,d) . In CDM3, the yield at day 15 was on average 5.5 × 10 5 TNNT2 + cells cm −2 , but as high as 1.25 × 10 6 TNNT2 + cells cm −2 , a 100-fold increase in cell number over the 1.25 × 10 4 hiPSCs plated at day −4 (4 d before induction of differentiation). We confirmed the specificity of flow cytometry staining conditions for this assay and observed similar percentages of TNNT2 + cardiomyocytes using three anti-troponin antibodies ( Supplementary Fig. 3g and Online Methods). We observed minimal cell death throughout differentiation ( Supplementary Fig. 5 ), and contraction began at days 7-9 ( Supplementary Videos 1-3 ).
Assessment of essential developmental pathways
We previously proposed that Wnt signaling initiates a paracrine feedback loop via signaling by FGF, BMP, Wnt and activin-Nodal, and may be responsible for mesoderm induction in hiPSCs 4 . To test this hypothesis and to determine whether more specific signaling pathway control could improve robustness of differentiation, we inhibited the six major pathways associated with in vivo cardiac differentiation: FGF, activin-Nodal, BMP, Wnt, TGFβ and MAPK 17 (Fig. 1e) . We added inhibitors of each of these pathways (11 total; Online Methods) at differentiation day 0-2 or day 1-2. Our results demonstrated that FGF, activin-Nodal, BMP and Wnt signaling are essential for mesoderm induction, as inhibition of npg these pathways hindered efficient cardiac differentiation. By contrast, TGFβ and p38 MAPK were dispensable ( Fig. 1e) . We then added each of the 11 inhibitors during differentiation days 2-4, 3-4 and 4-6. We found that by days 3-4, none of the six pathways were required because inhibition did not diminish or enhance the efficiency of differentiation ( Fig. 1f ).
cdm3 differentiation on defined matrices
We found that when using the synthetic vitronectin peptide 18 matrix, the highly motile cardiomyocyte monolayers would detach from the surface at ~day 15 ( Supplementary Fig. 6 ), irrespective of vitronectin peptide concentrations, which reduced the yield and increased variability. Although this lack of longterm adhesion could be resolved by passaging and replating, we sought a more suitable solution. We first assessed chemically defined pluripotent culture on other defined matrices: recombinant human E-cadherin 19 Fig. 7) . The use of laminin-based matrices resulted in higher growth rates compared to the vitronectin peptide when we correctly optimized surface densities ( Supplementary Fig. 8 ), potentially due to the established role of laminin-511 and laminin-521 interacting with α 6 β 1 integrin and activating the PI3K Akt pathway 24 .
Fibronectin-based matrices did not support pluripotent growth. All five suitable matrices supported efficient differentiation in CDM3 ( Supplementary Fig. 6 and Supplementary Videos 4-9), and we observed no differences in efficiency between cells cultured long-term (>6 passages) on the defined matrices and cells transferred to the matrix just before differentiation ( Supplementary Fig. 9 ). Only the laminin-based matrices maintained long-term adhesion (>15 d) during CDM3 cardiac differentiation ( Supplementary Fig. 6d ), but as these matrices are prohibitively expensive for large-scale application, we performed all subsequent characterization on the vitronectin peptide.
differentiation in multiple hiPsc lines
Cardiomyocytes produced by CDM3 differentiation were positive for cardiac markers (TNNT2 and α-actinin) and for the immature npg cardiomyocyte marker alpha smooth muscle actin (αSMA), and were negative for the endothelial marker von Willebrand factor (vWF) and the fibroblast marker P4HB. A small proportion of cells were positive for the proliferation marker Ki67 (Fig. 2a) . We tested our protocol with multiple human embryonic stem cell (hESC) and hiPSC lines (Online Methods) at passages between 25 and 80; we observed 80-95% differentiation efficiency for all lines and passage numbers tested, as assessed by flow cytometry for TNNT2 ( Fig. 2b) as well as yields of greater than 3 × 10 5 cardiomyocytes cm −2 . We could maintain cardiomyocytes in these chemically defined conditions for >200 d.
enrichment of cardiomyocytes with metabolic selection
Culturing hiPSC-derived cardiomyocytes in glucose-free MEMα supplemented with FBS and lactate has been shown to enrich cells from 4.5% to 98.0% α-actinin-positive 25 . By replacing the RPMI 1640 medium in CDM3 with RPMI 1640 medium without glucose and supplementing it with sodium dl-lactate ( Fig. 2c) , we found that 6-10 d of glucose deprivation enriched cardiomyocytes from ~85% TNNT2 + to >95% TNNT2 + (Fig. 2d) . This method cannot be used in media containing the B27 supplement because it contains a source of glucose (d(+)-galactose). We note that establishing the effects, if any, of metabolic manipulation of cardiomyocytes needs further study.
characterization of differentiated cardiomyocytes
We sampled the cells differentiating in CDM3 daily and examined gene expression patterns by real-time reverse-transcription (RT)-PCR ( Supplementary Fig. 10 ). Consistent with patterns reported for previous differentiation strategies 2,26 and with embryonic development, the pluripotency marker POU5F1 was rapidly downregulated at day 2 with concurrent upregulation of the mesoderm markers T and MIXL1, followed by upregulation of the cardiac mesoderm marker MESP1. Early cardiomyocyte markers (KDR, ISL, and GATA4) became highly expressed from days 5-6, with expression of later markers (NKX2-5, TBX5 and MEF2C) peaking at days 8-9. Finally, expression of cardiomyocyte myofilament genes TNNT2 and MYH6 peaked at days 8-10, and, as previously noted 2,8 , the expression subsequently decreased, likely owing to the comparatively slow turnover (~3-5 d; ref. 27) of these proteins once the myofilaments were established. Single-cell real-time RT-PCR on day 20 cardiomyocytes (not metabolically selected) showed substantial homogeneity among cells ( Fig. 2e) , although we noted more variation in the expression of the ion channel genes HCN1, HCN4, KCNQ1 and KCNH2. Many cells coexpressed markers of human atrial (NPPA, CX40 and SLN), ventricular (MLC2V and IRX4) 28 and nodal (TBX18) cells, which suggested that these day 20 cells are composed of, or still contain, unspecified cardiomyocytes without a fully defined subtype.
To assess the subtypes of cardiomyocytes derived in CDM3, we used flow cytometry to examine cells on days 10, 15, 25, 30, 45 and 60 of differentiation ( Fig. 3a, and Supplementary Figs. 11  and 12) . Expression of the two major isoforms of MLC2 (MLC2A and MLC2V) has been used previously to describe atrial versus ventricular specification of hPSC-derived cardiomyocytes 5, 6, 29 . In humans, MLC2A expression is detected in both the atria and ventricles during development 30 and in adult cardiomyocytes 31 . By contrast, MLC2V expression is restricted to the ventricles throughout development and persists into adulthood 30 . At day 10 of differentiation, cells demonstrated a TNNT2 + MLC2A + MLC2V − phenotype, likely representing unspecified cardiomyocyte precursors. The number of MLC2A + cells progressively decreased during differentiation, with a dramatic drop to ~10% after day 30, whereas numbers of MLC2V + cells consistently increased, reaching 60% at day 60 ( Fig. 3a) . We confirmed that antibodies labeled sarcomeres by immunofluorescence staining (Fig. 3b) and observed similar results in cells differentiated in RPMI + B27 − ins medium (Supplementary Fig. 11b) .
Patch-clamp analysis demonstrated that at days 15-20, cells had an atrial-like action potential with a low average maximum diastolic potential (MDP) of −55.2 ± 2.0 mV (±s.e.m.; Fig. 4a,b) . These cells likely represented unspecified cardiomyocyte precursors in the heart tube during development and not cells that had undergone atrial specification. At days 30-35, cardiomyocytes demonstrated a more heterogeneous phenotype, with ventricular-like cells being the predominant phenotype (57%, with an MDP of −57.8 mV) along with atrial-like and nodal-like cells ( Fig. 4c and Supplementary Table 4) . A second electrophysiological technique, nanopillar electroporation 32 confirmed that day 30 cells possessed a predominantly ventricular-like phenotype (Fig. 4d-f) . Taken together, these electrophysiological analysis data were consistent with our flow cytometry (Fig. 3a) , immunofluorescence (Fig. 3b) , and single-cell real-time RT-PCR ( Fig. 2e) findings, demonstrating that cells differentiated in CDM3 progressed from an unspecified cardiomyocyte precursor phenotype to an immature, predominantly ventricular phenotype.
discussion
A key surprising finding of our studies was how few medium components are required to differentiate a pluripotent cell to a cardiomyocyte. Of the 21 components in B27, only albumin was required, npg and the simple CDM3 medium consisting of three components (recombinant albumin, ascorbic acid and the basal medium RPMI 1640) supported cardiac differentiation at the same efficiency as RPMI + B27 − ins medium. Albumin can fulfill multiple roles in medium formulations, including acting as a detoxifier or buffer by binding lipids and excessive proteins, binding hormones and growth peptides to keep them stable, and binding free radicals to reduce oxidative damage to cells 33 . In CDM3, we used a rice-derived recombinant albumin and can therefore rule out the presence of mammalian albumin-associated proteins, lipids or small molecules. Removal of recombinant albumin from CDM3 did not result in cell death (as with removal of AA 2-P), but merely in a reduction in cardiomyocyte yield. Ascorbic acid is an antioxidant with a well-established role in improving cardiac differentiation 2,34 , potentially via increasing collagen synthesis that results in greater proliferation of cardiovascular progenitor cells 35 . The utility of ascorbic acid in E8 medium for pluripotent cell culture and during reprogramming raises the question of whether ascorbic acid is merely acting as an antioxidant in the cardiac differentiation system. Recently, ascorbic acid has been shown to produce widespread but targeted Tet-dependent DNA demethylation 36 , that may have a role during differentiation. RPMI 1640 medium is one of the simplest classical basal media, related to McCoy's 5A and consisting of 20 amino acids, inorganic salts, the eight B vitamins and the antioxidant glutathione. RPMI 1640 medium does not contain any lipids, iron or zinc, and elucidating the exact reason why this basal medium is superior in this protocol awaits further experimentation.
From repeatedly differentiating 11 hiPSC lines over a range of >60 passages, it became clear that reproducible, highly proliferative pluripotent growth and prevention of over-confluence was the primary determinant for successful differentiation.
The matrix to which the pluripotent cells are attached is integral in differentiation. In our study, laminin-based matrices were most successful for both the support of pluripotent hiPSC growth and long-term adherence of cardiomyocytes, as seen with human adult cardiomyocytes 31 . It has been demonstrated that hESC-derived cardiomyocytes express integrin α 3 , α 5 , α 6 , α 7 , α V , β 1 and β 5 (ref. 37) , very similar to the predominant expression of α 5 , α 6 , α V , β 1 and β 5 in pluripotent hESCs 20 . hESCs adhere to laminin-511, laminin-521 and Matrigel using the α 6 β 1 integrin 22 , likely explaining the similar long-term adherence performance. By contrast, pluripotent cells adhere to vitronectin using α V β 5 integrin 18, 20 , which has a lower binding affinity for its preferred substrates than does α 6 β 1 integrin 23 , and along with potential lower expression of α V β 5 on hiPSC cardiomyocytes, could explain the differences in long-term cardiomyocyte adherence.
In summary, the chemically defined differentiation medium CDM3 provides a reproducible, scalable method for deriving cardiomyocytes from hiPSCs. Although the cells remain immature, we propose that the chemically simple nature of CDM3, without factors that could skew subtype specification [38] [39] [40] , provides an excellent inert platform to screen for factors to produce mature atrial, ventricular and nodal cells. Finally, the defined CDM3 medium should help facilitate the translation of basic hiPSC research to the clinic by providing insights into the macromolecular requirements of cardiovascular progenitor cells and hiPSC-derived cardiomyocytes.
methods
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
online methods
Cultures. All pluripotent and reprogramming cultures were maintained at 37 °C in a New Brunswick Galaxy 170R humidified incubator (Eppendorf), with 5% CO 2 and 5% O 2 controlled by the injection of carbon dioxide and nitrogen. Primary cell and differentiation cultures were maintained at 5% CO 2 and atmospheric (21%) O 2 .
Human induced pluripotent cell derivation. Protocols were approved by the Stanford University Human Subjects Research Institutional Review Board. With informed written consent, two 2-mm skin punch biopsies were taken from each volunteer, diced with a scalpel, digested with 1 mg/ml collagenase IV (Life Technologies) for 2 h at 37 °C. Fibroblasts were then grown in DMEM with GlutaMAX (Life Technologies) supplemented with 10% FBS (US origin, Life Technologies) on six-well plates (Greiner) coated with a 1:200 dilution of growth factor-reduced Matrigel (9 µg/cm 2 , Corning). Medium was changed every other day. When confluent, fibroblasts were passaged with TrypLE Express (Life Technologies) onto Matrigel-coated T225 flasks (Nunc).
For Sendai virus-based reprogramming ( Supplementary  Fig. 1a) , early passage (passage 2 to passage 3) fibroblasts were seeded at 40,000 cells per well on Synthemax II-SC 18 (625 ng/cm 2 , Corning)-coated six-well plates. After 24 h, medium was changed to E8 medium 41 . The E8 formula was modified to replace human-derived transferrin with an Oryza sativa-derived recombinant version, to make the formula completely chemically defined. The successful application of Synthemax II-SC at the low concentration of 625 ng/cm 2 is in line with reports 42 that the minimal surface density of vitronectin protein is very low at 250 ng/cm 2 . E8 medium consisting of DMEM-F12 (50:50 mixture of DMEM and Ham's F12 medium; 10-092-CM, Corning), 20 µg/ml Escherichia coli-derived recombinant human insulin (Dance Pharmaceuticals/CS Bio), 64 µg/ml l-ascorbic acid 2-phosphate sesquimagnesium salt hydrate (Sigma-Aldrich), 10.7 µg/ml O. sativa-derived recombinant human transferrin (Optiferrin, Invitria/Sigma-Aldrich), 14 ng/ml sodium selenite (Sigma-Aldrich), 100 ng/ml recombinant human FGF2 (154 amino acid, E. coli-derived, Peprotech) and 2 ng/ml recombinant human TGFβ1 (112 amino acid, HEK293-derived, Peprotech). To the medium we added four OSKM CytoTune-iPS Sendai Reprogramming Kit viral particle factors (Life Technologies) 43 diluted ~1/5 on the basis of the manufacturer's recommendations (3 × 10 5 cell infectious units (CIU) of each particle per well, multiplicity of infection (MOI) = 7.5). Medium was changed after 24 h and thereafter once every day. For the first 7 d, cultures were maintained in E8 medium supplemented with 100 nM hydrocortizone (Sigma-Aldrich) and 200 µM sodium butyrate (Sigma-Aldrich) 44 . At day 7, medium was swapped to E7N (E8 minus TGFβ1; supplemented with 200 µM sodium butyrate). Medium switched to E8 medium at day 20.
For plasmid-based reprogramming 45 , pCXLE-hSK (27078), pCXLE-hUL (27080) and pCXLE-hOCT4-shp53 (27077) plasmids were obtained from Addgene. The OSKM codon-optimized mini-intronic plasmid (CoMiP) was generated. Plasmid-containing E. coli were grown in Miller's LB (Life Technologies), and purified using Plasmid Maxi Kit (QIAGEN) following manufacturer's instructions, and quantified using a NanoDrop 2000 (Thermo Scientific). 1 × 10 6 cells were electroporated with 6 µg total DNA (2 µg of each for three plasmid-based systems, 6 µg for CoMiP) using a Neon Transfection System (Life Technologies), with the settings: 1,650 V, 3 pulses, 10 ms, 100 µl tips, and buffers R and E2. Cells were plated on Synthemax II-SC-coated six-well plates.
For peripheral blood mononuclear cell (PBMC) reprogramming, 20 ml of blood was collected in EDTA-containing Vacutainer tubes (BD Biosciences). PBMCs were isolated using a Ficoll-Paque PLUS (1.077 g/ml) gradient (GE Healthcare) and plated at 1 million cells per milliliter in 2 ml of a humanized version of blood medium 46 comprised of 50:50 IMDM:F12 (both Life Technologies), 2 mg/ml recombinant human albumin, 1% v/v chemically defined lipid concentrate (Life Technologies), 10 µg/ml recombinant human insulin, 100 µg/ml recombinant human transferrin, 15 ng/ml sodium selenite, 64 µg/ml l-ascorbic acid 2-phosphate, 450 µM 1-thioglycerol (Sigma-Aldrich), 50 ng/ml SCF (Peprotech), 10 ng/ml IL3 (Peprotech), 2 U/ml EPO (EMD Millipore), 40 ng/ml IGF1 (Peprotech) and 1 µM dexamethasone (Sigma-Aldrich). Cells were cultured for 9 d with 50% medium changes every other day. After 9 d, 1 × 10 6 were plated in blood medium with Sendai virus, as above. Medium was changed every other day and were transferred to E7N medium in a Synthemax II-SC-coated six-well plate at day 3.
For all reprogramming methods, individual colonies with hESC morphology were picked into one well of a 12-well plate (one colony per well) at day 17 to day 25 in E8 medium with 2 µM thiazovivin for 24 h after picking. Subsequently, cells were expanded into six-well plates by passaging 1:1, 1:4, 1:6, 1:8 and finally 1:12, using 0.5 mM EDTA (Life Technologies) in D-PBS without CaCl 2 or MgCl 2 (Life Technologies) for 7 min at room temperature.
Human pluripotent stem cell culture. Cells were routinely maintained in E8 medium (made as above) on either Synthemax II-SC (625 ng/cm 2 ) or 1:200 growth factor-reduced Matrigel (9 µg/cm 2 ) and passaged every 4 d using 0.5 mM EDTA (as above). 2 µM thiazovivin (Selleck Chemicals) was added for the first 24 h after passage. Control hESC lines H7 (WA07) and H9 (WA09) 47 were supplied by WiCell Research Institute. All hESC and hiPSC lines were converted to E8 medium with EDTA-based culture for at least five passages before beginning differentiation. For the growth comparison experiment, cells were grown in mTeSR1 (Stemcell Technologies). Cell lines were used between passages 20 and 83. All cultures (primary, pluripotent and differentiation) were maintained with 2 ml medium per 9.6 cm 2 of surface area or equivalent. All pluripotent cultures were routinely tested for mycoplasma contamination using a MycoAlert Kit (Lonza).
Growth assays. To assess cell growth, cells were counted using a Countess automated cell counter (Life Technologies). For growth rate calculation, cells were seeded at 1.25 × 10 4 cells per cm 2 (120,000 cells per well of a 6-well plate) and grown for 96 h. Cumulative population doublings was calculated using the formula n = 3.32 (log 10 (N/N 0 ), where n is the number of population doublings, N is number of cells at passage, and N 0 is number of cells seeded).
Teratoma analysis. Three confluent wells of pluripotent cells were dissociated with EDTA, centrifuged, resuspended in 100 µl of growth factor-reduced Matrigel, and injected into the kidney npg capsule of female 12-24 week-old nonobese diabetic severe combined immunodeficiency mice (NOD.CB17-Prkdc scid /NcrCrl strain code 394, Charles River). After 4-6 weeks, teratomas were removed, fixed in 4% PFA, embedded in paraffin wax, sectioned and hematoxylin and eosin (H&E) stained by members of the Stanford Tissue Bank. Slides were imaged and analyzed by a qualified clinical pathologist. Animal studies were approved by Stanford Institution Review Board and Stem Cell Research Oversight committees.
Immunofluorescence staining. hiPSCs or cardiomyocytes were plated onto Synthemax II-SC-coated Lab-Tek II eight-chamber glass slides (154524, Nunc) and were allowed to grow for 3 d. Cells were fixed with 4% PFA (Electron Microscopy Services) for 15 min at room temperature, permeabilized with 0.1% Triton-X (Sigma-Aldrich) for 10 min at room temperature, blocked in 10% goat serum (Sigma-Aldrich) and 0.1% Triton-X for 15 For optimization of cardiac troponin T (TNNT2) flow cytometry staining, we stained fibroblasts (45 min, primary) with the TNNT2 antibody 13-11 and observed a very minor increase in staining over the isotype control (Supplementary Fig. 3g ). We also assessed additional monoclonal antibodies for cardiac troponin T (1-C11) and cardiac troponin I (7E147), each from a different manufacturer, and found similar levels of positive cell detection (~85-88%) (Supplementary Fig. 3g ). As part of our optimization we also assessed overnight primary antibody staining with the TNNT2 13-11 antibody and found that this method gave us nonspecific staining in fibroblasts and raised the percentage of TNNT2 + cells to >99%. Therefore we used 45 min staining as above (Supplementary Fig. 3g ).
Quantitative real-time PCR.
To analyze gene expression, cells were dissociated with TryPLE Express, and pellets of cells were snap-frozen in liquid nitrogen and stored at −80 °C. RNA was isolated using an RNeasy Plus kit (QIAGEN), cDNA was produced using a High Capacity RNA-to-cDNA kit (Life Technologies), and real-time PCR was performed using TaqMan Gene Expression Assays ( Supplementary Table 5 ), TaqMan Gene Expression Master Mix, and a 7900HT Real-Time PCR System (all Life Technologies). All PCR reactions were performed in triplicate, normalized to the 18S endogenous control gene, and assessed using the comparative change in threshold cycle (∆C t ) method.
Single-cell quantitative real-time PCR.
To analyze single-cell gene expression, cells were dissociated as above, and a 300,000 cells/ml suspension was prepared. The cell suspension was loaded onto a 17-25 µm C 1 Fluidigm chip for single-cell capture and treated with a LIVE/DEAD Viability/Cytotoxicity Kit (Life Technologies). The C 1 chip was then imaged under phasecontrast and fluorescence microscopes to exclude doublets and dead cells from subsequent PCR analysis. Single-cell lysis, reverse transcription and preamplification were all performed on the C 1 chip using the C 1 Single Cell Auto Prep (Fluidigm) and Single Cell-to-CT kits (Ambion). Reverse transcription was performed at 25 °C for 10 min, 42 °C for 1 h, and finally 85 °C for 5 min. Preamplification was performed at 95 °C for 10 min, followed by 18 cycles of 95 °C for 15 s, and 60 °C for 4 min. Amplified cDNA products were harvested from the C 1 chip into 96-well 0.2 ml PCR plates and then loaded onto Biomark 48.48 Dynamic Array chips using the Nanoflex IFC controller (Fluidigm). Quantitative single-cell PCR was performed using gene amplification with TaqMan Assays (Life Technologies) ( Supplementary Table 6 ), and C t as a measurement of relative fluorescence intensity was extracted by the BioMark Real-Time PCR Analysis software. All PCR reactions were performed in duplicate or triplicate, and C t values were directly used in data analysis after normalization to the 18S endogenous control gene.
Patch clamp. To record cellular action potentials, cardiomyocytes at day 15 were dissociated using TrypLE for 10 min, filtered through a 100 µM cell strainer (BD Biosciences), counted with a Countess Cell Counter, plated as single cells (1 × 10 5 cells per well of a 24-well plate) on 8 mm no. 1 glass cover slips (Warner Instruments) coated with Synthemax II-SC (625 ng/cm 2 ) in CDM3 supplemented with 2 µM thiazovivin and allowed to attach for 72 h, changing the medium every other day. Cells were then npg
